{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:51:39Z","timestamp":1786737099797,"version":"build-2736575974"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Endocr Metab"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/ijem.ijem_579_19","type":"journal-article","created":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T01:25:21Z","timestamp":1588209921000},"page":"206","source":"Crossref","is-referenced-by-count":6,"title":["Parathyroid hormone replacement versus oral calcium and active vitamin D supplementation in hypoparathyroidism: A meta-analysis"],"prefix":"10.4103","volume":"24","author":[{"given":"Jayaprakash","family":"Sahoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan","family":"Palui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RashmiRanjan","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayan","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadishkumar","family":"Kamalanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SitanshuSekhar","family":"Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhiya","family":"Selvarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AmitKumar","family":"Satapathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2230-8210.283552-1","doi-asserted-by":"crossref","first-page":"17055","DOI":"10.1038\/nrdp.2017.55","article-title":"Hypoparathyroidism","author":"Mannstadt","year":"2017","journal-title":"Nat Rev Dis Primer"},{"key":"key-10.4103\/2230-8210.283552-2","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1210\/jc.2018-02228","article-title":"Auditing the efficacy and safety of alfacalcidol and calcium therapy in idiopathic hypoparathyroidism","author":"Saha","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.283552-3","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00198-009-1149-x","article-title":"Therapy of hypoparathyroidism with intact parathyroid hormone","author":"Rubin","year":"2010","journal-title":"Osteoporos Int"},{"key":"key-10.4103\/2230-8210.283552-4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12020-017-1377-3","article-title":"Quality of life in patients with hypoparathyroidism receiving standard treatment: A systematic review","author":"B\u00fcttner","year":"2017","journal-title":"Endocrine"},{"key":"key-10.4103\/2230-8210.283552-5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000479867","article-title":"Continuous subcutaneous recombinant parathyroid hormone (1\u201334) infusion in the management of childhood hypoparathyroidism associated with malabsorption","author":"Saraff","year":"2018","journal-title":"Horm Res Paediatr"},{"key":"key-10.4103\/2230-8210.283552-6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1\u201384) in hypoparathyroidism (REPLACE): A double-blind, placebo-controlled, randomised, phase 3 study","author":"Mannstadt","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key-10.4103\/2230-8210.283552-7","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/jbmr.470","article-title":"The effect of adding PTH (1-84) to conventional treatment of hypoparathyroidism: A randomized, placebo-controlled study","author":"Sikjaer","year":"2011","journal-title":"J Bone Miner Res"},{"key":"key-10.4103\/2230-8210.283552-8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.1996.03540080053029","article-title":"Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism","author":"Winer","year":"1996","journal-title":"JAMA"},{"key":"key-10.4103\/2230-8210.283552-9","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1210\/jc.2002-021736","article-title":"Long-term treatment of hypoparathyroidism: A randomized controlled study comparing parathyroid hormone-(1\u201334) versus calcitriol and calcium","author":"Winer","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.283552-10","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1210\/jc.2009-2464","article-title":"Long-term treatment of 12 children with chronic hypoparathyroidism: A randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium","author":"Winer","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.283552-11","first-page":"137\u201344","article-title":"Therapy of hypoparathyroidism with PTH(1\u201384): A prospective four-year investigation of efficacy and safety","author":"Cusano","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.283552-12","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1210\/jc.2015-1855","article-title":"PTH(1\u201334) for surgical hypoparathyroidism: A prospective, open-label investigation of efficacy and quality of life","author":"Santonati","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.283552-13","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1210\/jc.2015-4135","article-title":"Therapy of hypoparathyroidism with PTH(1\u201384): A prospective six year investigation of efficacy and safety","author":"Rubin","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.283552-14","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.ecl.2018.07.013","article-title":"New directions in treatment of hypoparathyroidism","author":"Tabacco","year":"2018","journal-title":"Endocrinol Metab Clin North Am"},{"key":"key-10.4103\/2230-8210.283552-15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1210\/er.2003-0024","article-title":"Parathyroid hormone secretion and action: Evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl- terminal ligands","author":"Murray","year":"2005","journal-title":"Endocr Rev"},{"key":"key-10.4103\/2230-8210.283552-16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000491047","article-title":"A new era for chronic management of hypoparathyroidism: Parathyroid hormone peptides","author":"Marcucci","year":"2019","journal-title":"Front Horm Res"},{"key":"key-10.4103\/2230-8210.283552-17","first-page":"377","article-title":"Parathyroid hormone replacement therapy in hypoparathyroidism: A meta-analysis","author":"Liu","year":"2016","journal-title":"Horm Metab Res"},{"key":"key-10.4103\/2230-8210.283552-18","unstructured":"Available from: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42017067452. [Last accessed on 2018 Oct 29]."},{"key":"key-10.4103\/2230-8210.283552-19","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"key-10.4103\/2230-8210.283552-20","unstructured":"Available from: http:\/\/www. ClinicalTrials.gov\/. [Last accessed on 2018 Jul 31]."},{"key":"key-10.4103\/2230-8210.283552-21","unstructured":"Available from: http:\/\/www.who.int\/ictrp\/en\/. [Last accessed on 2018 Jul 31]."},{"key":"key-10.4103\/2230-8210.283552-22","doi-asserted-by":"crossref","unstructured":"Higgins JP, Altman DG. Assessing risk of bias in included studies. In: Higgins JP, Green S, editor. Cochrane Handbook for Systematic Reviews of Interventions; 2008.","DOI":"10.1002\/9780470712184"},{"key":"key-10.4103\/2230-8210.283552-23","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014."},{"key":"key-10.4103\/2230-8210.283552-24","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","article-title":"GRADE guidelines: 14.Going from evidence to recommendations: The significance and presentation of recommendations","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"key-10.4103\/2230-8210.283552-25","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/jbmr.3543","article-title":"The effects of long-term administration of rhPTH (1-84) in hypoparathyroidism by bone histomorphometry","author":"Rubin","year":"2018","journal-title":"J Bone Miner Res"},{"key":"key-10.4103\/2230-8210.283552-26","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1210\/jc.2015-1477","article-title":"The effect of treatment with PTH on undercarboxylated osteocalcin and energy metabolism in hypoparathyroidism","author":"Harsl\u00f8f","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.283552-27","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1001\/jamaoto.2015.1497","article-title":"Teriparatide therapy and reduced postoperative hospitalization for postsurgical hypoparathyroidism","author":"Shah","year":"2015","journal-title":"JAMA Otolaryngol Neck Surg"},{"key":"key-10.4103\/2230-8210.283552-28","first-page":"53","article-title":"Teriparatide (rhPTH) treatment in children with syndromic hypoparathyroidism","author":"Matarazzo","year":"2014","journal-title":"J Pediatr Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.283552-29","first-page":"322","article-title":"[Reduction in requirements of oral calcium and 1-25 dihydroxy vitamin D in patients with post-surgical hypoparathyroidism treated with teriparatide (PTH1-34)]","author":"Guti\u00e9rrez-Cerecedo","year":"2016","journal-title":"Gac Med Mex"},{"key":"key-10.4103\/2230-8210.283552-30","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jbmr.2588","article-title":"PTH (1-84) administration in hypoparathyroidism transiently reduces bone matrix mineralization","author":"Misof","year":"2016","journal-title":"J Bone Miner Res"},{"key":"key-10.4103\/2230-8210.283552-31","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00198-015-3377-6","article-title":"Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: A prospective study","author":"Sumida","year":"2016","journal-title":"Osteoporos Int"},{"key":"key-10.4103\/2230-8210.283552-32","doi-asserted-by":"crossref","first-page":"415","DOI":"10.4103\/ijem.IJEM_340_16","article-title":"Efficacy of teriparatide in patients with hypoparathyroidism: A prospective, open-label study","author":"Upreti","year":"2017","journal-title":"Indian J Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.283552-33","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1002\/jbmr.3554","article-title":"Comparative effect of rhPTH(1-84) on bone mineral density and trabecular bone score in hypoparathyroidism and postmenopausal osteoporosis","author":"Cipriani","year":"2018","journal-title":"J Bone Miner Res"},{"key":"key-10.4103\/2230-8210.283552-34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1210\/jc.2017-01555","article-title":"PTH(1\u201334) for surgical hypoparathyroidism: A 2-year prospective, open-label investigation of efficacy and quality of life","author":"Palermo","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.283552-35","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1210\/jc.2014-2267","article-title":"PTH(1\u201384) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy","author":"Cusano","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.283552-36","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1210\/jc.2013-1239","article-title":"The effect of PTH(1\u201384) on quality of life in hypoparathyroidism","author":"Cusano","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.283552-37","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s00198-014-2677-6","article-title":"Effects of PTH(1\u201384) therapy on muscle function and quality of life in hypoparathyroidism: Results from a randomized controlled trial","author":"Sikjaer","year":"2014","journal-title":"Osteoporos Int"},{"key":"key-10.4103\/2230-8210.283552-38","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1210\/jc.2017-01471","article-title":"Recombinant human parathyroid hormone effect on health-related quality of life in adults with chronic hypoparathyroidism","author":"Vokes","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.283552-39","first-page":"3480","article-title":"A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1\u201334 in treatment of hypoparathyroidism","author":"Sarani","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.283552-40","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/j.clinthera.2017.08.011","article-title":"Safety and efficacy of recombinant human parathyroid hormone in adults with hypoparathyroidism randomly assigned to receive fixed 25-\u03bcg or 50-\u03bcg daily doses","author":"Bilezikian","year":"2017","journal-title":"Clin Ther"},{"key":"key-10.4103\/2230-8210.283552-41","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1210\/jc.2007-2552","article-title":"Effects of once versus twice-daily parathyroid hormone 1\u201334 therapy in children with hypoparathyroidism","author":"Winer","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.283552-42","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00268-017-4248-4","article-title":"Recombinant parathyroid hormone versus usual care: Do the outcomes justify the cost?","author":"Chomsky-Higgins","year":"2018","journal-title":"World J Surg"},{"key":"key-10.4103\/2230-8210.283552-43","first-page":"391","article-title":"Synthetic human parathyroid hormone 1-34 replacement therapy: A randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism","author":"Winer","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.283552-44","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1210\/jc.2011-1359","article-title":"Long-term results of continuous subcutaneous recombinant PTH (1-34) infusion in children with refractory hypoparathyroidism","author":"Linglart","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.283552-45","first-page":"708","article-title":"Efficacy and safety of long term treatment of unresponsive hypoparathyroidism using multipulse subcutaneous infusion of teriparatide","author":"D\u00edaz-Soto","year":"2012","journal-title":"Horm Metab Res"},{"key":"key-10.4103\/2230-8210.283552-46","doi-asserted-by":"crossref","unstructured":"Winer KK, Fulton KA, Albert PS, Cutler GB. Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism. J Pediatr 2014;165:556-63.e1.","DOI":"10.1016\/j.jpeds.2014.04.060"},{"key":"key-10.4103\/2230-8210.283552-47","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1002\/jbmr.1964","article-title":"PTH (1-84) replacement therapy in hypoparathyroidism: A randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment","author":"Sikjaer","year":"2013","journal-title":"J Bone Miner Res"},{"key":"key-10.4103\/2230-8210.283552-48","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.chembiol.2013.12.016","article-title":"Vitamin D metabolism, mechanism of action, and clinical applications","author":"Bikle","year":"2014","journal-title":"Chem Biol"},{"key":"key-10.4103\/2230-8210.283552-49","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2265.2006.02479.x","article-title":"Pattern of bone mineral density in patients with sporadic idiopathic hypoparathyroidism","author":"Laway","year":"2006","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:50:07Z","timestamp":1786733407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.IJEM_579_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"alternative-id":["283552"],"URL":"https:\/\/doi.org\/10.4103\/ijem.ijem_579_19","relation":{},"ISSN":["2230-8210"],"issn-type":[{"value":"2230-8210","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}